This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

4 Breakout Stocks to Watch Going Into Labor Day

NEW YORK (TheStreet) -- A lot of stocks we follow closely are doing very well, and here are four to watch for continued upside.

Arista Networks  (ANET) did very well on Wednesday. It exploded from just under $76, ran up to $83.47, and closed at $83.15, up $6.99, or 9.2%, on 724,200 shares traded. That's a lot of volume for that stock, and the best volume in about two-and-a-half weeks. With the breakout across lateral resistance at recent highs, this stock could head up towards $92-$93 in the short term. At around $82.50, shares are up nearly 50% for the year to date.

Read More: 10 Stocks Carl Icahn Loves in 2014

BioDelivery Sciences International (BDSI) , one of our swing trade picks, is also acting well. It popped 5% on Wednesday, up 82 cents to $15.48, breaking through lateral resistance and the double-top that's been holding it back since July. The target is $19 and then $21. At close to $16, the stock is up 169% for the year to date.

Keryx Biopharmaceuticals  (KERX) appears to be breaking out. Intermediate resistance in the $18 range was taken out on Wednesday, as the stock gained 95 cents, or 5.5%, to $18.18. Watch for a move next to the $20 range short-term, and then secondary target at $22-$22.50. Shares are currently around $18, up 39% for the year to date.

Sunesis Pharmaceuticals  (SNSS) popped on Wednesday, up 74 cents, or about 10%, to $8.23 on 5.2 million shares. That's the biggest volume since the beginning of the year, and comes on a breakout day when it moved across resistance going back to late 2012. At this point, look for SNSS to run to $12 and then potentially to $15. Shares, at close to $8, are up nearly 65% year to date.

Read More: 7 Stocks Warren Buffett Is Selling in 2014

See Harry's video chart analysis on these stocks.

At the time of publication, the author held no positions in any of the stocks mentioned, although positions may change at any time.

This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.


TheStreet Ratings team rates KERYX BIOPHARMACEUTICALS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:

"We rate KERYX BIOPHARMACEUTICALS INC (KERX) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and poor profit margins."

You can view the full analysis from the report here: KERX Ratings Report

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs